Fig. 14: The pS129-a-synpositive cells were detected by immunofluorescence staining. | npj Parkinson's Disease

Fig. 14: The pS129-a-synpositive cells were detected by immunofluorescence staining.

From: Adjusting vascular permeability, leukocyte infiltration, and microglial cell activation to rescue dopaminergic neurons in rodent models of Parkinson’s disease

Fig. 14

a–j The immunostaining of pS129-α-syn+ cells (red) in the striatum showed that the expression of pS129-α-syn+ was increased in vehicle-treated PD models (b, g) compared to normal controls (a, f). Treatment with C16 (c, h), Ang-1 (d, i), and especially C16 plus Ang-1 (e, j) inhibited the upregulation of pS129-α-syn+ in PD animals. Image “aa” shows the enlarged image within the square frame of (h). The white arrow indicates pS129-α-syn+ staining. The nuclei of cells were labeled with Hoechst33342 (blue). Scale bar = 100 µm. k Quantification of pS129-α-syn+ cells. a p < 0.05 versus the normal control group; b p < 0.05 versus the vehicle group; c p < 0.05 versus the C16-treated group; d p < 0.05 versus the Ang-1-treated group. pS129-α-synuclein, plasma Ser129-phosphorylated α-synuclein; C16, peptide (KAFDITYVRLKF) that can selectively bind integrin ανβ3; Ang-1, angiopoietin-1.

Back to article page